Sedana Medical’s Sedaconda study presented at ESICM
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that outcomes from some of the secondary endpoints of the company’s pivotal study, Sedaconda (SED-001, formerly known as the IsoConDa-study) were presented at the leading congress ESICM LIVES 2020, 6-9 December, 2020.Secondary endpoints of the study demonstrate that Sedaconda (isoflurane), delivered via AnaConDa, compared to propofol, enables · Shorter and predictable wake-up · Reduced need of opiates · Higher proportion of spontaneous breathing (which increases the conditions for maintained lung function during and